^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    1d
    TRIDENT: Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=80, Recruiting, Corcept Therapeutics | N=60 --> 80
    Enrollment change
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • Lifyorli (relacorilant)
    1d
    Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=1132, Recruiting, Hoffmann-La Roche | N=792 --> 1132
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • eribulin mesylate • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • giredestrant (RG6171) • Actemra IV (tocilizumab) • atirmociclib (PF-07220060) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    1d
    CHORUS: A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • Ilaris (canakinumab)
    1d
    Sarcomatoid Transformation of Pulmonary Mucinous Adenocarcinoma as a Mechanism of Immunotherapy Resistance. (PubMed, Thorac Cancer)
    As surgical resection was not feasible, first-line treatment with ipilimumab plus nivolumab combined with chemotherapy was initiated, resulting in a partial response...Thirteen months later, the patient developed radiographic worsening of ILD, for which oral prednisolone was initiated...The patient received two cycles of nab-paclitaxel plus carboplatin without response and subsequently died. These findings emphasize that clinicians should recognize that IMA may undergo sarcomatous transformation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • NKX2-1 (NK2 Homeobox 1) • VIM (Vimentin)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • prednisolone
    1d
    GS-US-742-7757: Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (2025-524095-27-00)
    P1/2, N=45, Not yet recruiting, Gilead Sciences Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 negative
    |
    Opdivo (nivolumab) • albumin-bound paclitaxel • Cyramza (ramucirumab) • denikitug (GS-1811)
    1d
    SIAG-BTC: Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC. (clinicaltrials.gov)
    P2, N=107, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Yervoy (ipilimumab) • gemcitabine • Tyvyt (sintilimab) • albumin-bound paclitaxel
    3d
    Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=63, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 amplification + HR-positive • HER-2 overexpression + HR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel
    3d
    TitAN: Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study (clinicaltrials.gov)
    P2, N=34, Recruiting, Qilu Hospital of Shandong University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    3d
    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P1, N=21, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    gemcitabine • albumin-bound paclitaxel
    3d
    Nimotuzumab combined with gemcitabine and nab-paclitaxel as first-line therapy for advanced pancreatic cancer: a single-arm, single-center Phase II prospective study. (PubMed, Front Med (Lausanne))
    The NTZ-AG regimen demonstrated meaningful anti-tumor activity and an acceptable safety profile as first-line therapy for unselected advanced pancreatic cancer patients, providing a rational basis for larger randomized controlled trials. This trial was registered at the Chinese Clinical Trial Register (ChiCTR) under the registration number ChiCTR2300072843 having URL https://www.chictr.org.cn/showprojEN.html?proj=198791.
    Clinical • P2 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab)
    4d
    Distinct multiplex immunofluorescence-based immune and stromal marker expression profile of subcutaneously metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report. (PubMed, Transl Lung Cancer Res)
    The patient received four cycles of tislelizumab combined with albumin-bound paclitaxel and carboplatin, followed by four cycles of tislelizumab monotherapy maintenance. The distinct marker expression profile in subcutaneous metastatic lesions (high CD56, PD-1, and pan-CK expression with low CD8, CD68, and CD20 expression) reflects the unique TME of SMARCA4-UT, which may be related to its metastatic potential and immunotherapeutic response. Chemotherapy combined with immunotherapy shows promising efficacy in the treatment of SMARCA4-UT, and the mIF-based marker profile may provide a potential basis for optimizing individualized treatment strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NCAM1 (Neural cell adhesion molecule 1) • CD68 (CD68 Molecule)
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    4d
    A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) (clinicaltrials.gov)
    P3, N=446, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • albumin-bound paclitaxel • izalontamab brengitecan (BL-B01D1)